Roche announced a $3.5 billion acquisition of biotech firm 89bio, gaining control of pegozafermin, a drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASH), a liver disease stemming from inflammation-induced fibrosis. This move positions Roche within a growing therapeutic area linked to obesity-related liver conditions. The deal includes a $14.50 per share cash payment, representing an 80% premium, plus contingent value rights totaling up to $6 per share. Shareholders stand to benefit from the transaction valued at an equity amount of $2.4 billion. This acquisition amplifies Roche's presence in metabolic diseases and underscores increasing pharma interest in MASH treatment development.